LUKAS BIOMEDICAL INC. Financials Lukas Biomedical Inc.
Equities
6814
TW0006814007
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.1 TWD | +0.33% |
|
-4.44% | +2.73% |
| 03-26 | Lukas Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Lukas Biomedical Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 1,775 | 1,374 | 1,162 | 1,080 |
| Enterprise Value (EV) 1 | 1,948 | 1,531 | 1,234 | 1,174 |
| P/E ratio | -168 x | -27.8 x | -23.1 x | -22.8 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 9.79 x | 8.72 x | 6.29 x | 4.66 x |
| EV / Revenue | 10.7 x | 9.71 x | 6.68 x | 5.07 x |
| EV / EBITDA | 54.7 x | -83 x | -48.1 x | -44.7 x |
| EV / FCF | 90.1 x | -192 x | 144 x | 317 x |
| FCF Yield | 1.11% | -0.52% | 0.69% | 0.32% |
| Price to Book | 6.1 x | 4.79 x | 3.55 x | 3.86 x |
| Nbr of stocks (in thousands) | 32,874 | 32,874 | 36,874 | 36,874 |
| Reference price 2 | 54.00 | 41.80 | 31.50 | 29.30 |
| Announcement Date | 4/6/21 | 4/28/22 | 4/27/23 | 4/11/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 132.4 | 152.9 | 181.4 | 157.6 | 184.8 | 231.8 |
| EBITDA 1 | 20.44 | 36.1 | 35.6 | -18.44 | -25.63 | -26.3 |
| EBIT 1 | -2.438 | -2.636 | -5.304 | -42.83 | -48.47 | -43.56 |
| Operating Margin | -1.84% | -1.72% | -2.92% | -27.17% | -26.23% | -18.79% |
| Earnings before Tax (EBT) 1 | -22.04 | -7.791 | -9.956 | -47.83 | -49.92 | -47.28 |
| Net income 1 | -27.8 | -6.989 | -10.54 | -49.49 | -50.07 | -47.35 |
| Net margin | -20.99% | -4.57% | -5.81% | -31.4% | -27.1% | -20.43% |
| EPS 2 | -1.011 | -0.2126 | -0.3207 | -1.506 | -1.362 | -1.284 |
| Free Cash Flow 1 | 18.82 | -15.05 | 21.63 | -7.958 | 8.546 | 3.706 |
| FCF margin | 14.21% | -9.84% | 11.92% | -5.05% | 4.62% | 1.6% |
| FCF Conversion (EBITDA) | 92.07% | - | 60.75% | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/15/20 | 12/15/20 | 4/6/21 | 4/28/22 | 4/27/23 | 4/11/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 75.4 | 190 | 173 | 156 | 72 | 94.1 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.688 x | 5.251 x | 4.86 x | -8.485 x | -2.807 x | -3.577 x |
| Free Cash Flow 1 | 18.8 | -15 | 21.6 | -7.96 | 8.55 | 3.71 |
| ROE (net income / shareholders' equity) | -7.38% | -2.29% | -3.56% | -17.1% | -16.3% | -15.6% |
| ROA (Net income/ Total Assets) | -0.32% | -0.32% | -0.61% | -5.08% | -5.99% | -5.91% |
| Assets 1 | 8,662 | 2,175 | 1,717 | 975.3 | 835.5 | 800.8 |
| Book Value Per Share 2 | 9.370 | 9.170 | 8.850 | 8.720 | 8.880 | 7.600 |
| Cash Flow per Share 2 | 1.600 | 1.220 | 1.190 | 1.970 | 1.090 | 0.8600 |
| Capex 1 | 11.5 | 63.5 | 8.68 | 10 | 2.98 | 2.66 |
| Capex / Sales | 8.68% | 41.53% | 4.79% | 6.36% | 1.61% | 1.15% |
| Announcement Date | 12/15/20 | 12/15/20 | 4/6/21 | 4/28/22 | 4/27/23 | 4/11/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +2.73% | 34.54M | |
| -4.98% | 182B | |
| +2.84% | 112B | |
| -2.68% | 68.58B | |
| +4.53% | 51.58B | |
| +8.00% | 44.24B | |
| +9.45% | 43.65B | |
| +25.30% | 32.46B | |
| +20.94% | 25.99B | |
| -0.17% | 25.61B |
- Stock Market
- Equities
- 6814 Stock
- Financials Lukas Biomedical Inc.